Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1989 Jan;75(1):161–165.

A rat model of captopril immunogenicity.

A L Foster 1, J W Coleman 1
PMCID: PMC1541848  PMID: 2467767

Abstract

Following chronic administration of the protein-reactive sulphydryl drug captopril (CP) to rats, an IgG antibody response to CP-derived antigen was detected by ELISA in rats administered the free drug at doses of 270 mumol/kg (i.p. and i.m.) and 27 mumol/kg (i.p.). The antibody response was slow to develop, requiring three series of four daily injections at one-monthly intervals before CP-specific serum IgG was apparent. The IgG antibody recognized CP-ovalbumin but not ovalbumin, and was inhibited by CP in protein-conjugated form, and by free CP and CP-disulphide, thus confirming specificity for a CP-derived antigenic determinant. A drug-induced non-drug-specific IgG response directed against human serum albumin was also observed after chronic high dose CP treatment. No IgG anti-DNA, IgM anti-CP nor IgM anti-HSA responses were seen following chronic drug administration. These studies show that CP, like the model reactive metabolite dinitrofluorobenzene, but unlike other protein-reactive drugs such as D-penicillamine and benzylpenicillin, is immunogenic in the rat. The findings also suggest the possibility that anti-CP antibodies reported in man may be drug-induced, rather than naturally occurring.

Full text

PDF
161

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Binderup L., Bramm E., Arrigoni-Martelli E. Captopril(SQ 14,225): in vitro and in vivo influence on the proliferative response of rat lymphocytes. Experientia. 1982 Mar 15;38(3):399–401. doi: 10.1007/BF01949416. [DOI] [PubMed] [Google Scholar]
  2. Christie G., Coleman J. W., Park B. K. Drug-protein conjugates--XVII. The effect of storage on the antigenicity and immunogenicity of benzylpenicillin in the rat. Biochem Pharmacol. 1988 Nov 1;37(21):4121–4128. doi: 10.1016/0006-2952(88)90105-0. [DOI] [PubMed] [Google Scholar]
  3. Coleman J. W., Foster A. L., Yeung J. H., Park B. K. Drug-protein conjugates--XV. A study of the disposition of D-penicillamine in the rat and its relationship to immunogenicity. Biochem Pharmacol. 1988 Feb 15;37(4):737–742. doi: 10.1016/0006-2952(88)90148-7. [DOI] [PubMed] [Google Scholar]
  4. Coleman J. W., Yeung J. H., Roberts D. H., Breckenridge A. M., Park B. K. Drug-specific antibodies in patients receiving captopril. Br J Clin Pharmacol. 1986 Aug;22(2):161–165. doi: 10.1111/j.1365-2125.1986.tb05244.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Delfraissy J. F., Galanaud P., Balavoine J. F., Wallon C., Dormont J. Captopril and immune regulation. Kidney Int. 1984 Jun;25(6):925–929. doi: 10.1038/ki.1984.111. [DOI] [PubMed] [Google Scholar]
  6. Edwards C. R., Padfield P. L. Angiotensin-converting enzyme inhibitors: past, present, and bright future. Lancet. 1985 Jan 5;1(8419):30–34. doi: 10.1016/s0140-6736(85)90975-4. [DOI] [PubMed] [Google Scholar]
  7. Foster A. L., Park B. K., Coleman J. W. A specific enzyme-linked immunosorbent assay for definition of the IgG antibody response to disulphide-conjugated D-penicillamine in the rabbit. Int Arch Allergy Appl Immunol. 1987;84(3):271–276. doi: 10.1159/000234434. [DOI] [PubMed] [Google Scholar]
  8. Hoorntje S. J., Kallenberg C. G., Weening J. J., Donker A. J., The T. H., Hoedemaeker P. J. Immune-complex glomerulopathy in patients treated with captopril. Lancet. 1980 Jun 7;1(8180):1212–1215. doi: 10.1016/s0140-6736(80)91677-3. [DOI] [PubMed] [Google Scholar]
  9. Kallenberg C. G., Hoorntje S. J., Smit A. J., Weening J. J., Donker A. J., Hoedemaeker P. H., The T. H. Antinuclear and antinative DNA antibodies during captopril treatment. Acta Med Scand. 1982;211(4):297–300. doi: 10.1111/j.0954-6820.1982.tb01948.x. [DOI] [PubMed] [Google Scholar]
  10. Kallenberg C. G., van der Laan S., de Zeeuw D. Captopril and the immune system. Lancet. 1981 Jul 11;2(8237):92–92. doi: 10.1016/s0140-6736(81)90441-4. [DOI] [PubMed] [Google Scholar]
  11. Kitteringham N. R., Christie G., Coleman J. W., Yeung J. H., Park B. K. Drug-protein conjugates--XII. A study of the disposition, irreversible binding and immunogenicity of penicillin in the rat. Biochem Pharmacol. 1987 Mar 1;36(5):601–608. doi: 10.1016/0006-2952(87)90708-8. [DOI] [PubMed] [Google Scholar]
  12. Park B. K., Coleman J. W., Kitteringham N. R. Drug disposition and drug hypersensitivity. Biochem Pharmacol. 1987 Mar 1;36(5):581–590. [PubMed] [Google Scholar]
  13. Park B. K., Grabowski P. S., Yeung J. H., Breckenridge A. M. Drug protein conjugates--I. A study of the covalent binding of [14C]captopril to plasma proteins in the rat. Biochem Pharmacol. 1982 May 1;31(9):1755–1760. doi: 10.1016/0006-2952(82)90680-3. [DOI] [PubMed] [Google Scholar]
  14. Park B. K., Tingle M. D., Grabowski P. S., Coleman J. W., Kitteringham N. R. Drug-protein conjugates--XI. Disposition and immunogenicity of dinitrofluorobenzene, a model compound for the investigation of drugs as haptens. Biochem Pharmacol. 1987 Mar 1;36(5):591–599. doi: 10.1016/0006-2952(87)90707-6. [DOI] [PubMed] [Google Scholar]
  15. Smit A. J., Van der Laan S., De Monchy J., Kallenberg C. G., Donker A. J. Cutaneous reactions to captopril. Predictive value of skin tests. Clin Allergy. 1984 Sep;14(5):413–419. doi: 10.1111/j.1365-2222.1984.tb02224.x. [DOI] [PubMed] [Google Scholar]
  16. Wong K. K., Lan S., Migdalof B. H. In vitro biotransformations of [14C]captopril in the blood of rats, dogs and humans. Biochem Pharmacol. 1981 Oct 1;30(19):2643–2650. doi: 10.1016/0006-2952(81)90532-3. [DOI] [PubMed] [Google Scholar]
  17. Yeung J. H., Coleman J. W., Park B. K. Drug-protein conjugates--IX. Immunogenicity of captopril-protein conjugates. Biochem Pharmacol. 1985 Nov 15;34(22):4005–4012. doi: 10.1016/0006-2952(85)90380-6. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES